FDA authorizes antibiotic for community-acquired bacterial pneumonia
Category: #healthcare  By Mateen Dalal  Date: 2019-08-21
  • share
  • Twitter
  • Facebook
  • LinkedIn

FDA authorizes antibiotic for community-acquired bacterial pneumonia
  • Xenleta (lefamulin) will be given Priority Review by FDA to act over its application in a quicker time frame.
     
  • The Food and Drug Administration approved Xenleta to Nabriva Therapeutics.    

The Food and Drug Administration authorized Xenleta (lefamulin), a new antibiotic released for the treatment of community-acquired bacterial pneumonia (CABP) in adults. 

Director of FDA’s Office of Antimicrobial Products, ED Cox, M.P.H., M.D., stated that new drug released offers another option to treat patients suffering from community-acquired bacterial pneumonia, which is a serious disease. It is crucial for patients and physicians to have options for treatment for such a disease.

Cox added that this approval would reinforce FDA’s present commitment to treat infectious diseases by easily facilitating new antibiotics development.

Community-acquired pneumonia develops when an individual is infected by pneumonia in a community setting and not a hospital. Pneumonia is a kind of lung infection which can range from mild to a severe illness. It can affect people of all age groups.

Reports from Centers for Disease Control & Prevention indicate that almost one million people get hospitalized every year because of community-acquired pneumonia with about 50,000 people dying in the United States.

The efficacy and safety of Xenleta, taken intravenously or orally, was examined in 1,289 total patients with CABP. Xenleta was compared to moxifloxacin, without or with linezolid. The trials concluded that individuals treated with Xenleta had same clinical success rates as those treated with moxifloxacin without or with linezolid.

Xenleta got Qualified Infectious Disease Product (QIDP) from FDA. This QIDP designation is earned by antifungal and antibacterial drug products developed to treat life-threatening or serious infections below the Generating Antibiotic Incentives Now (GAIN) of the FDA Safety & Innovation Act. As a component of QIDP designation, the antibiotic was given Priority Review under which FDA aims to act over the application in a quicker time frame.

The Food and Drug Administration approved Xenleta to Nabriva Therapeutics.     

About Author

Mateen Dalal    

Mateen Dalal

Despite working as a professional testing engineer, Mateen Dalal always held a liking for content creation. Following his passion, he now pens down articles for itresearchbrief.com and a couple of similar portals. Mateen is a qualified electronics and telecommunicat...

Read More>>

More News By Mateen Dalal

Coherent’s shares surge by 33% after Lumentum reveals acquisition plans
Coherent’s shares surge by 33% after Lumentum reveals acquisition plans
By Mateen Dalal

Coherent Inc., an American leading provider of lasers and laser-based technologies, witnessed a 33% ...

Mercedes Benz India planning to launch 15 new vehicles in 2021
Mercedes Benz India planning to launch 15 new vehicles in 2021
By Mateen Dalal

According to reliable sources, luxury car manufacturer Mercedes Benz India Pvt. Ltd. is planning on ...

AltPep Corporation raises USD 23.15 million in Series A funding round
AltPep Corporation raises USD 23.15 million in Series A funding round
By Mateen Dalal

According to reliable sources, U.S.-based privately held biomedical organization AltPep Corporation ...